云南白药集团股份有限公司 2、药品事业群 2024 年经营情况如何？ 答：2024 年药品事业群主营业务收入 69.24 亿元，同比增长 11.8%， 单品销售过亿产品达 10 个。核心系列产品中，云南白药气雾剂销售 收入突破 21 亿元，同比增长超 26%；云南白药膏、云南白药胶囊、 云南白药创可贴、云南白药（散剂）均在上年销售收入基础上，实现 显著增长。其他品牌中药类产品增长亮眼，蒲地蓝消炎片销售收入近 2 亿元，同比大幅增长超 22%，血塞通胶囊、小儿宝泰康颗粒、参苓 健脾胃颗粒产品收入均破亿。植物补益类产品，气血康口服液销售收 入继续保持增长态势，同口径下同比增长约 14%。 投资者调研会议记录 时间：2025 年 7 月 9 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：平安基金-王华、丁琳，信达证券-章钟涛、王留阳 参加人员：投资者关系管理-张昱、杨可欣 会议内容 1、请问公司 2025 年一季度业绩情况如何？ 答：2025 年第一季度，公司实现营业收入 108.41 亿元，同比增 长 0.62%；归母净利润 19.35 亿元，同比增长 13.67%；扣非归母净利 润 18.87 亿元， ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2025 年 7 月 8 日 地点：集团总部办公大楼 召开方式：现场调研 答：（1）研发能力强、领军人才储备丰富：云南白药与北京大 学联合成立北大—白药国际医学研究中心，在公司首席科学家张宁教 授带领下，依托北大在药物开发领域的创新引领能力和人才储备，利 用北大的大数据资源与生信分析等前沿技术，高效进行药物新靶点的 发掘。同时，校企联动，建立高效的可开发性评价、体外活性评价、 动物模型与体内评价、临床研究评价等体系，打造基于大数据的源头 创新研发平台。（2）产业链整合能力强：云南白药通过子公司云核 医药整合天津、北京、上海、昆明等研发资源，并与国内顶尖科研机 构深化合作，加强构筑源头创新能力，同时积极与核药产业链相关部 门、科研院所、核药企业、医疗机构等建立和深化战略合作，加速在 核药产业链上、中、下游的布局。（3）前瞻性战略布局：2022 年云 南白药围绕国家医用同位素战略发展需求和北京大学核医学研究优 势，成立了中央研究院创新药物中心，在肿瘤、免疫等领域布局，打 造以精准诊疗、独具优势的核药为中心的创新药研发管线，较早地认 识到核药在解决国内临床患者未被 ...

特此通告。 黑龙江省药品监督管理局 2025年7月2日 黑龙江省药品监督管理局药品GMP符合性检查结果通告（2025年 第6号） 按照《药品管理法》及《国家药监局关于实施新修订<药品生产监督管理办法>有关事项的公告》（2020年第47号）要求，经现场检查哈尔滨三联药业股份 有限公司等16家企业符合《药品生产质量管理规范（2010年修订）》要求。 药品GMP符合性检查企业目录（2025年 第6号） | 序 | 符合性 | 企业名 | | | 现场 | | | --- | --- | --- | --- | --- | --- | --- | | 号 | 检查编 | 称 | 检查范围 | 生产地址 | 检查 | 备注 | | | 号 | | | | 时间 | | | 1 | 黑药符 | 哈尔滨 三联药 | 311车间小容量注射剂生产线:小容量注射剂（非最终灭菌） （抗肿瘤药） | | 2025 年4月 | | | | 查 | 业股份 | | 哈尔滨市利民开发区北京路 | 26日 | | | | 2025034 | 有限公 | | | —4月 | | | | | 司 | | | 29日 | | | 2 | 查 | ...

全品类规模效应+原料自给，盈利能力高。公司已具备完整的主流单剂自主生产能力，产品线覆盖清净 剂、分散剂、ZDDP、高温抗氧剂等多个系列，涵盖完整的主流添加剂单剂品种。且公司具备十二烷基 酚、3.5-甲酯等重要原材料生产能力，整体盈利能力较高，24 年公司毛利率为35.9%，同比+0.82pct。 国内与海外业务并举，开启新增长极。公司积极开拓海外市场，在新加坡、迪拜、比利时等地设立海外 仓储基地。24 年公司国外收入达22.26 亿元，同比增长8.2%，占比70.5%。公司在建项目"年产15 万吨 润滑油添加剂系列项目"二期、"年产46 万吨润滑油添加剂系列项目"预计将于2025 年底建成达产，未来 三年公司产能将迈向70 万吨以上，规模与成本优势进一步放大。 风险提示：产能投放进度不及预期、市场推广不及预期、贸易政策变化等。 【主要逻辑】技术驱动转型，API 认证持续突破。近年来公司研发投入持续上升。 截至24 年公司已获得授权国内发明专利47 项、国外发明专利2 项、实用新型专利4 项。公司目前已自主 掌握CF-4 级、CH-4 级、CI-4 级、CK-4 级柴油机油复合剂配方工艺，SL 级、SM 级、S ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2025 年 6 月 19 日 地点：集团总部办公大楼 答：2025 年第一季度，公司实现营业收入 108.41 亿元，同比增 长 0.62%；归母净利润 19.35 亿元，同比增长 13.67%；扣非归母净利 润 18.87 亿元，同比增长 11.65%；基本每股收益 1.08 元/股，同比增 长 13.66%；经营活动产生的现金流量净额 7.14 亿元，同比增长 35.39%； 加权平均净资产收益率 4.86%，同比增长 0.68 个百分点；货币资金余 额 110.62 亿元，总资产 542.53 亿元。 召开方式：现场调研 投资者：中信证券-李文涛，中金公司-朱言音，平安证券-韩盟盟、 曹艳凯，圆和资本-陈家华 会议内容 1、请问公司 2025 年一季度业绩情况如何？ 2、药品事业群 2024 年取得较好业绩的原因是什么？ 答：2024 年，药品事业群以'伤科疼痛全领域管理的'第一' 品牌'为战略指引，结合产品和品牌禀赋，发布伤痛管理新模式，深 挖白药核心产品在伤科疼痛领域的药效机制，通过'白药+痛舒+伤痛' 相关产品在学术临床方面的深度挖潜，持续打造 ...

根据《中华人民共和国药品管理法》《药品生产监督管理办法》《药品生产质量管理规范》等法律法规规章，经现场检查和综合评定，现将国药集团威奇达 药业有限公司等14家药品生产企业药品GMP符合性现场检查结果予以通告（见附件）。 山西省药品监督管理局 2025年6月3日 转自：山西省药品监督管理局网站 山西省药品监督管理局药品GMP符合性检查结果通告 药品GMP符合性检查企业目录 | 序 | 企业名 | 检查地址 | 检查范围 | 检查时 | 检 查 | | --- | --- | --- | --- | --- | --- | | 号 | 称 | | | 间 | 结 | | | | | | | 果 | | | 国药集 | | | 2025年 | 符 | | | 团威奇 | | | 1月16 | 合 | | 1 | 达药业 | 山西省大同市经济技术开发区高新技术产业园 | 硬胶囊剂（青霉素类）（青霉素口服制剂二车间：Ⅴ线） | | | | | 有限公 | | | 日-1月 | 要 | | | | | | 19日 | 求 | | | 司 | | | | | | | | 持有人地址：山西省大同经济技术开发区思贤街 | | ...

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] Pharmaceutical Business Growth - The pharmaceutical segment focused on "comprehensive management of pain in the injury field" as a strategic direction [3] - The segment enhanced its core products' efficacy in pain management through academic clinical research [4] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, with ongoing efforts to enrich the product pipeline [4] - Marketing strategies included the successful cultivation of proprietary sports IP, which contributed to brand youthfulness and increased product penetration [4] Oral Care Product Performance - In 2024, Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - During major sales events like "618" and "Double Eleven," the brand consistently ranked first in online oral care sales [5] - Content marketing initiatives, such as the "Healthy Oral 123 Plan," significantly enhanced brand visibility, achieving over 6.43 billion exposures [6] Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [7] - The total cash dividend for 2024, including special dividends, amounted to 23.98 CNY per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising stability and safety results reported in November [9] - The company’s subsidiary received approval for clinical trials of INR102, an innovative drug for treating metastatic castration-resistant prostate cancer [9]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Pharmaceutical Business Development - The pharmaceutical segment focused on establishing itself as the leading brand in pain management, launching a new pain management model [3] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, enhancing the product pipeline [4] - Clinical research in diabetes foot, skeletal pain, and other areas showed steady progress, expanding product application scenarios [4] - Marketing efforts included the successful promotion of the proprietary sports IP "Let's Go Play Ball," enhancing brand youthfulness [4] - The company optimized its operational platform, achieving significant quality and efficiency improvements throughout the year [4] Health Products Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in toothpaste [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats [6] - The channel advantages have significantly enhanced market competitiveness and laid a foundation for new product commercialization [6] Future Development Strategy - The company aims for growth through both "internal" and "external" collaborative development, optimizing its industrial portfolio [7] - "Internal" development focuses on enhancing efficiency and stability across the pharmaceutical, health, and distribution sectors [7] - "External" development involves strategic mergers and collaborations to overcome growth bottlenecks and build a sustainable industrial system [7] Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, with no stock dividends [8] - A special dividend of 12.13 CNY per 10 shares was completed in November 2024, totaling 2.164 billion CNY [8] - The total cash dividend for 2024 amounts to 23.98 CNY per 10 shares, totaling 4.279 billion CNY, which is 90.09% of the net profit attributable to shareholders [9]

Core Viewpoint - The innovative drug sector has become a focal point in the A-share market, with Shuyou Shen (300204.SZ) emerging as a standout performer, experiencing significant stock price increases despite ongoing operational challenges [1][5]. Stock Performance - On June 4, Shuyou Shen opened high but closed at 30.79 CNY per share, down 3.18% from the previous day. The stock price surged from 11.04 CNY to 31.80 CNY between May 20 and June 3, marking a 188.04% increase over 10 trading days. From a low of 5.90 CNY on April 9, the stock has risen by 438.98% [2][11]. - The company's market capitalization increased by approximately 12.4 billion CNY due to the stock price surge [15]. - Institutional investors played a significant role in the stock's rise, with substantial buying activity noted on multiple trading days [13][14]. Financial Performance - Despite the stock price increase, Shuyou Shen's operational performance remains under pressure, with a 33.45% year-on-year decline in revenue for Q1. The net profit attributable to shareholders was -2.34 million CNY, although this represented a 38.05% reduction in losses compared to the previous year [2][19]. - The company has reported cumulative losses exceeding 1 billion CNY over five consecutive years from 2020 to 2024 [3][19]. - In 2024, the company’s revenue from its main products, Shutaqing and Sutai Sheng, declined, with sales of Shutaqing at 1.79 billion CNY (down 8.20%) and Sutai Sheng at 1.34 billion CNY (down 17.30%) [19]. Research and Development - Shuyou Shen's R&D investment dropped significantly to 162 million CNY in 2024, a decrease of 63.84% year-on-year [4][20]. - The company has reduced its R&D personnel by 14.75%, with R&D staff now comprising 21.14% of the total workforce [20]. - Despite the decline in R&D spending, the company has multiple I-class innovative biological drugs in clinical trials and is focused on advancing projects in areas such as neurological diseases and infectious diseases [20].

Core Insights - The SIAL Shanghai International Food Exhibition took place from May 19 to 21, attracting over 5,000 exhibitors from 75 countries and regions, and 180,000 professionals from 110 countries and regions [1] - Longkou San, a century-old pharmaceutical company focused on throat health, showcased its full range of products, particularly those aimed at protecting the throat health of the elderly, which garnered significant media and audience attention [1] Group 1: Demographics and Health Concerns - By the end of 2024, the population aged 60 and above in China is expected to reach 310 million, accounting for 22% of the total population, with throat health issues becoming a national concern post-pandemic [3] - As people age, they experience a decline in lung function and muscle strength in the throat, leading to potential health issues such as hoarseness, chronic cough, and swallowing difficulties, making proactive throat care essential for the elderly [3] Group 2: Product Offerings - Longkou San has developed a specialized product line for the throat care needs of the elderly, featuring a natural herbal and sugar-free formula that addresses various scenarios from daily protection to throat treatment [4] - The classic aluminum can powder product contains natural herbal ingredients like Platycodon, Almond, and Licorice, is non-addictive, and can be consumed without water, allowing the fine powder to adhere directly to the throat mucosa [4] - The herbal sugar-free throat lozenges are designed for daily throat care, available in four flavors, and are convenient for on-the-go use, promoting throat health without raising blood sugar levels [6] Group 3: Brand Engagement and Market Position - At the exhibition, Longkou San engaged the audience through interactive activities, attracting many attendees to learn more about the brand and its products [8] - The participation in SIAL showcased Longkou San's expertise and commitment to throat health, effectively communicating its philosophy of making throat care a daily routine, thereby enhancing public awareness, especially among the elderly [8]